VIP Research Peptide Overview

VIP (Vasoactive Intestinal Peptide) is a naturally occurring 28‐amino acid neuropeptide found throughout the gut, lungs, brain, and immune system. In preclinical research, it has drawn considerable attention for its wide‐ranging roles in inflammation control, vascular regulation, and neuroprotection.

At its core, VIP works by binding to two receptors, VPAC1 and VPAC2, which are found on immune cells, smooth muscle, and tissues throughout the body. When activated, these receptors trigger a signaling cascade that raises intracellular cAMP levels, ultimately dialing down inflammation and relaxing smooth muscle. What makes VIP particularly interesting to researchers is how many different systems this single mechanism appears to influence:

• Anti‐inflammatory activity: VIP consistently suppresses pro‐inflammatory signals like TNF‐α, IL‐6, and IL‐12, and nudges the immune response away from aggressive Th1 activity toward a more regulated Th2 profile.

• Smooth muscle relaxation: VIP relaxes smooth muscle in the airways, blood vessels, and gut, which is why it appears in research on pulmonary hypertension, asthma, and gastrointestinal motility.

• Neuroprotection: In preclinical models, VIP has shown a capacity to support neurotrophic factor expression and protect neurons, with studies exploring its relevance in Parkinson's and Alzheimer's related research.

• Antifibrotic effects: VIP has shown an ability to slow or limit fibrotic remodeling in lung, heart, and gut tissue models, making it of interest in chronic inflammatory disease research.

Integrated Research Applications

VIP has become a fairly versatile research tool because its effects touch so many systems at once. Some of the main areas researchers have explored include:

• Pulmonary and cardiovascular models: VIP is perhaps best known in pulmonary research. Animal studies show that mice lacking the VIP gene develop features resembling pulmonary arterial hypertension, suggesting VIP plays a role in keeping pulmonary vascular tone in check. A synthetic version called aviptadil has been investigated in early stage trials for PAH and lung injury.

• Immune and autoimmune models: VIP has been studied extensively in colitis, arthritis, and multiple sclerosis models, where its receptor signaling helps regulate the balance between protective and damaging immune responses.

• Gut and barrier research: VIP supports gut motility, mucosal blood flow, and the integrity of the intestinal lining, making it relevant to inflammatory bowel disease and barrier dysfunction research.

• Brain and neurodegenerative models: Researchers use VIP to study neuroplasticity, synapse maintenance, and neuron‐glia communication, particularly in models of age related neurodegeneration.

• Circadian biology: VIP is a key signaling molecule in the brain's master clock and is studied for its role in synchronizing circadian rhythms across organ systems.

Analytical Validation, Formulation, and Storage

Research grade VIP is supplied as a lyophilized white powder in glass vials, with no active formulation for administration.

Formulation: Lyophilized powder for reconstitution with an appropriate solvent; supplied without dosing instructions of any kind.

Storage follows standard peptide handling practice:

• Store lyophilized vials in a cool, dark, dry place; long‐term storage at or below −20 °C is recommended.

• After reconstitution, keep refrigerated at 2–8 °C, avoid repeated freeze thaw cycles, and use within laboratory defined timeframes.

NextGenPeps supplies VIP as a high purity research peptide intended strictly for controlled laboratory use in vitro or in established animal models, such as murine systems. This compound is not approved as a drug, diagnostic, or dietary ingredient, and is not manufactured, packaged, or marketed for consumption, self‐experimentation, clinical application, or any use outside properly designed and ethically approved research protocols.